- Weight-Loss Drug Zepbound May Lower Heart Failure Deaths
- Nearly 160 Million Americans Harmed by Another’s Drinking, Drug Use
- 1 in 4 Americans Now Struggling to Cover Medical Costs
- Getting Fitter Can Really Help Keep Dementia at Bay
- Skin Patch Could Monitor Your Blood Pressure
- There May Be a Better Way to Treat Hematoma Brain Bleeds
- Chronic Joint Pain Plus Depression Can Take Toll on the Brain
- Living in Space Won’t Permanently Harm Astronauts’ Thinking Skills
- Kids’ Injuries in Sports and at Home: When Is It Right to Seek Medical Attention?
- Human Cell Atlas Will Be ‘Google Maps’ for Health Research
Is It COVID, Flu or RSV? New At-Home Test May Tell
Americans will soon be able to self-test at home to find out whether they have COVID-19, the flu or another common germ, respiratory syncytial virus (RSV).
The first nonprescription test that can spot all three respiratory viral illnesses was approved Monday by the U.S. Food and Drug Administration and will be available at retail stores or online.
“While the FDA has now authorized many COVID-19 tests without a prescription, this is the first test authorized for flu and RSV, along with COVID-19, where an individual can self-identify their need for a test, order it, collect their sample and send it to the lab for testing, without consulting a health care professional,” Dr. Jeff Shuren said in an FDA news release. He directs the agency’s Center for Devices and Radiological Health.
With the polymerase chain reaction (PCR) test from North Carolina-based Labcorp, users collect their own nasal swab sample at home and then ship it to one of the company’s labs to be analyzed. Typical turnaround time for results is one to two days after the sample arrives at the lab, according to Labcorp, NBC News reported.
Other tests to detect multiple respiratory viruses typically require people to see a health care provider, who collects the nasal swab sample and ships it to a lab for analysis.
The Labcorp test kit costs $169, company spokesperson Chris Allman told NBC News.
That price isn’t surprising since people are getting three tests in one, said Jennifer Smith, an epidemiologist at the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health.
She told NBC News that the new test is likely to increase access to testing, particularly for people who may not be able to go into a clinic to get a test or for those don’t feel comfortable getting tested.
COVID, flu and RSV cause tens of thousands of deaths a year and a test that detects all three is “sort of the Holy Grail,” Dr. Michael Mina, a former Harvard epidemiologist, told NBC News. He’s now the chief science officer for eMed, a company that provides telehealth and at-home testing services.
More information
Find out more about the new test at the FDA.
SOURCES: U.S. Food and Drug Administration, news release, May 16, 2022; NBC News
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.